Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605719 · ClinicalTrials.gov registry record · Phase 1
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03605719 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 23 participants.
The verdict
NCT03605719, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of wild-type reovirus (pelareorep) when given together with dexamethasone, carfilzomib, and nivolumab in treating patients with multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. A virus, called pelareorep, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. Giving dexamethasone, carfilzomib, and nivolumab with pelareorep may work better in treating patients with multiple myeloma.
Interventions
- DRUG Dexamethasone
- BIOLOGICAL Nivolumab
- DRUG Carfilzomib
- BIOLOGICAL Pelareorep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2022-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03605719
The ClinicalTrials.gov registry entry for NCT03605719 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT03605719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03605719 about?
NCT03605719 is a clinical study titled "Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma". This phase I trial studies the side effects and best dose of wild-type reovirus (pelareorep) when given together with dexamethasone, carfilzomib, and nivolumab in treating patients with multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as dexamethasone, work in differe...
What is the current status of trial NCT03605719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-10-24. Estimated completion is 2022-10-10.
What interventions are being tested in trial NCT03605719?
The interventions under investigation include: Dexamethasone (DRUG), Nivolumab (BIOLOGICAL), Carfilzomib (DRUG), Pelareorep (BIOLOGICAL).
Who is sponsoring clinical trial NCT03605719?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.